

**Fig. S7. Comparison of the PDAC**<sup>EV</sup> **signature and SSTR2 in different patient cohorts.** The statistical significance of the PDAC<sup>EV</sup> signature (EPCAM, EGFR, MUC1, WNT2, and GPC1) and SSTR2 was evaluated in different cohorts of patients. **(A)** PDAC and PDAC treated with neoadjuvant regimen (p = 0.0015). **(B)** PDAC, IPMN, and age-matched controls (p = 0.022, p < 0.0001). **(C)** SSTR2 for PDAC, neuroendocrine tumors (NET), and age-matched controls (p < 0.0001, p = 0.0018). **(D)** Benign cystic tumor and age-matched controls (p = 0.35). The p-values were calculated using the nonparametric Mann Whitney test for two groups. For more than two groups, the p-values for pairwise comparisons were calculated using the Dunn's multiple comparison test.